Glenmark Generics gets US FDA nod
06 November 2014 | News | By BioSpectrum Bureau
Glenmark Generics gets US FDA nod for ulcer treatment drug
The drug has received final approval for 10, 20, and 40 mg strengths of Omeprazole
Glenmark Generics has announced that it has received approval from the United States Food and Drugs Administration (US FDA) to market generic version of AstraZeneca's Prilosec, a drug used for treatment of ulcer.
"Glenmark Generics (GGI) has been granted the final abbreviated new drug approval (ANDA) from the US FDA for Omeprazole Delayed Release Capsules, their generic version of Prilosec by AstraZeneca," the company said in a statement.
The company has received final approval for 10, 20, and 40 mg strengths of Omeprazole.
According to IMS sales data, for the 12 month period ending September 2014, Omeprazole garnered annual sales of approximately $520 million.
